158
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Coated hydralazine hydrochloride beads for sustained release after oral administration

, , , &
Pages 1439-1446 | Received 26 Apr 2012, Accepted 06 Aug 2012, Published online: 12 Oct 2012

References

  • Agrawal AM, Howard MA, Neau SH. (2004). Extruded and spheronized beads containing no microcrystalline cellulose: influence of formulation and process variables. Pharm Dev Technol, 9:197–217.
  • Davis SS, Hardy JG, Wilson CG, eds. (1989). Drug delivery to the gastro-intestinal tract. Chishester: Ellis Horwood, Ltd.
  • Jain SK, Jain A, Gupta Y, Ahirwar M. (2007). Design and development of hydrogel beads for targeted drug delivery to the colon. AAPS PharmSciTech, 8:E56.
  • Das S, Deshmukh R, Jha AK. (2010). Role of natural polymers in the development of multiparticulate systems for colon drug targeting. Syst Rev Pharm, 9:79–85.
  • Nurulaini H, Wong TW. (2011). Design of in situ dispersible and calcium cross-linked alginate pellets as intestinal-specific drug carrier by melt pelletization technique. J Pharm Sci, 100:2248–2257.
  • Roy P, Shahiwala A. (2009). Multiparticulate formulation approach to pulsatile drug delivery: current perspectives. J Control Release, 134:74–80.
  • Meyer JH, Elashoff J, Porter-Fink V, Dressman J, Amidon GL. (1988). Human postprandial gastric emptying of 1–3-millimeter spheres. Gastroenterology, 94:1315–1325.
  • Blok D, Arndt JW, de Haan FHN, Vermeij P, Junginger HE, Pauwels EKJ. (1991). Scintigraphic investigation of the gastric emptying of 3 mm pellets in human volunteers. Int J Pharm, 73:171–176.
  • Stotzer PO, Abrahamsson H. (2000). Human postprandial gastric emptying of indigestible solids can occur unrelated to antral phase III. Neurogastroenterol Motil, 12:415–419.
  • Madamba MC, Mullett WM, Debnath S, Kwong E. (2007). Characterization of tablet film coatings using a laser-induced breakdown spectroscopic technique. AAPS PharmSciTech, 8:E103.
  • Mayo-Pedrosa M, Alvarez-Lorenzo C, Lacík I, Martinez-Pacheco R, Concheiro A. (2007). Sustained release pellets based on poly(N-isopropyl acrylamide): matrix and in situ photopolymerization-coated systems. J Pharm Sci, 96:93–105.
  • Liao YC, Lee DJ. (1997). Slow release from a coated sphere with slight deformations of coating film and drug matrix. J Pharm Sci, 86:92–100.
  • Leong CW, Newton JM, Basit AW, Podczeck F, Cummings JH, Ring SG. (2002). The formation of colonic digestible films of amylose and ethylcellulose from aqueous dispersions at temperatures below 37 degrees C. Eur J Pharm Biopharm, 54:291–297.
  • Siew LF, Basit AW, Newton JM. (2000). The properties of amylose-ethylcellulose films cast from organic-based solvents as potential coatings for colonic drug delivery. Eur J Pharm Sci, 11:133–139.
  • Milojevic S, Newton JM, Cummings JH, Gibson GR, Botham RL, Ring SG, Stockham M, Allwood MC. (1996). Amylose as a coating for drug delivery to the colon: Preparation and in vitro evaluation using 5-aminosalicylic acid pellets. J Control Rel, 38:75–84.
  • He W, Du Q, Cao DY, Xiang B, Fan LF.(2007). Pectin/ethylcellulose as film-coatings for colon-specific drug delivery preparation and in vitro evaluation using 5-fluorouracil pellets. PDA J Pharm Sci Tech, 61:121–130.
  • McConnell EL, Tutas J, Mohamed MAM, Banning D, Basit AW. (2007). Colonic drug delivery using amylose films: the role of aqueous ethylcellulose dispersions in controlling drug release. Cellulose, 14:25–34.
  • Karrout Y, Neut C, Siepmann F, Wils D, Ravaux P, Deremaux L et al. (2010). Enzymatically degraded Eurylon 6 HP-PG: ethylcellulose film coatings for colon targeting in inflammatory bowel disease patients. J Pharm Pharmacol, 62:1676–1684.
  • He W, Du Q, Cao DY, Xiang B, Fan LF. (2008). In-vitro and in-vivo studies of pectin/ethylcellulose-film coated pellets of 5-fluorouracil for colonic targeting. J Pharm Pharmacol, 60:35–44.
  • Rubinstein A, Radai R. (1995). In vitro and in vivo analysis of colon specificity of calcium pectinate formulations. Eur J Pharm Biopharm, 41:291–295.
  • Semdé R, Amighi K, Devleeschouwer MJ, Moës AJ. (2000). Effect of pectinolytic enzymes on the theophylline release from pellets coated with water insoluble polymers containing pectin HM or calcium pectinate. Int J Pharm, 197:169–179.
  • Zhang M, Li XH, Gong YD, Zhao NM, Zhang XF. (2002). Properties and biocompatibility of chitosan films modified by blending with PEG. Biomaterials, 23:2641–2648.
  • Hutchings D, Kuzmak B, Sakr A. (1994). Processing considerations for an EC latex coating system: influence of curing time and temperature. Pharm Res, 11:1474–1478.
  • Mulrow JP, Crawford MH. (1989). Clinical pharmacokinetics and therapeutic use of hydralazine in congestive heart failure. Clin Pharmacokinet, 16:86–89.
  • Ford GA, Katzir D, Blaschke TF, Hoffman BB. (1991). Responsiveness of peripheral veins to vasodilators and the effect of nifedipine on alpha-adrenergic responsiveness in hypertension. Clin Pharmacol Ther, 50:192–198.
  • Mason DT. (1978). Afterload reduction and cardiac performance. Physiologic basis of systemic vasodilators as a new approach in treatment of congestive heart failure. Am J Med, 65:106–125.
  • Jack DB, Kendall MJ, Dean S, Laugher SJ, Zaman R, Tenneson ME. (1982). The effect of hydralazine on the pharmacokinetics of three different beta adrenoceptor antagonists: metoprolol, nadolol, and acebutolol. Biopharm Drug Dispos, 3:47–54.
  • Svensson CK, Knowlton PW, Ware JA. (1987). Effect of hydralazine on the elimination of antipyrine in the rat. Pharm Res, 4:515–518.
  • Bolt GR, Saxena PR. (1984). Interaction of atenolol with the systemic and regional hemodynamic effects of hydralazine in conscious renal hypertensive rabbits. J Pharmacol Exp Ther, 230:205–213.
  • Chong DY, Michel T. (2008). Pharmacology of vascular tone. In: Golan DE, Tashjian AH, Armstrong EJ, Armstrong AW, eds. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy, 2nd ed.. Philadelphia: Lippincott, Williams & Wilkins, 367–386.
  • Shepherd AM, Ludden TM, McNay JL, Lin MS. (1980). Hydralazine kinetics after single and repeated oral doses. Clin Pharmacol Ther, 28:804–811.
  • Onodera T, Takayama S, Yamada A, Ono Y, Akimoto T. (1978). Toxicological studies of 1-[2-(1,3-dimethyl-2-butenylidene)-hydrazino]-phthalazine, a new antihypertensive drug, in mice and rats. Toxicol Appl Pharmacol, 44:431–439.
  • Koch-Weser J. (1976). Medical intelligence drug therapy. N Engl J Med, 295:320–323.
  • Lesser JM, Israili ZH, Davis DC, Dayton PG. (1974). Metabolism and disposition of hydralazine-14C in man and dog. Drug Metab Dispos. 29:351–360.
  • Al-Suwayeh SA, El-Shaboury MH, Al-Baraki SM, Elgorashy AS, Taha EL. (2009). In vitro and in vivo evaluation of sustained release hydralazine hydrochloride tablets prepared by thermal granulation technique. Aust J Basic Appl Sci, 3:2866–2875.
  • Ludden TM, Rotenberg KS, Ludden LK, Shepherd AM, Woodworth JR. (1988). Relative bioavailability of immediate- and sustained-release hydralazine formulations. J Pharm Sci, 77:1026–1032.
  • Ranade VV. (1991). Drug delivery systems 5B. Oral drug delivery. J Clin Pharmacol, 31:98–115.
  • Singh B, Pahuja S, Kapil R, Ahuja N. (2009). Formulation development of oral controlled release tablets of hydralazine: optimization of drug release and bioadhesive characteristics. Acta Pharm, 59:1–13.
  • http://www.ashland.com/Ashland/Static/Documents/AAFI/Sell%20Sheets/SS_HER50922-2_Aquarius_SRX.pdf (Accessed 8 July 2012).
  • Kramer A, Turk S, Vrecer F. (2003). Statistical optimization of diclofenac sustained release pellets coated with polymeric films. Int J Pharm, 256:43–52.
  • Higuchi T. (1963). Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci, 52:1145–1149.
  • Higuchi T. (1961). Rate of release of medicaments from ointment bases containing drugs in suspension. J Pharm Sci, 50:874–875.
  • Das Gupta V, Stewart KR, Bethea C. (1986). Stability of hydralazine hydrochloride in aqueous vehicles. J Clin Hosp Pharm, 11:215–223.
  • Marsano E, Bianchi E, Sciutto L. (2003). Microporous thermally sensitive hydrogels based on hydroxypropyl cellulose crosslinked with poly-ethyleneglicol diglycidyl ether. Polymer, 44:6835–6841.
  • Roshdy MN, Schnaare RL, Sugita ET, Schwartz JB. (2002). The effect of controlled release tablet performance and hydrogel strength on in vitro/in vivo correlation. Pharm Dev Technol, 7:155–168.
  • Kamel S, Ali N, Jahangir K, Shah SM, El-Gendy AA. (2008). Pharmaceutical significance of cellulose: a review. eXPRESS Polym Lett, 2:758–778.
  • Ravi Kumar MNV, Kumar N, Domb AJ, Arora M. (2002). Filled elastomers drug delivery systems. In: Arora M, ed. Advances in Polymer Science Vol. 160. New York: Springer-Verlag, 45–118.
  • http://www.aapsj.org/abstracts/AM_2008/AAPS2008-003015.PDF (Accessed 25 July 2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.